1. Clinical and Pharmacokinetic Factors Associated With Adalimumab-Induced Mucosal Healing in Patients With Crohn’s Disease 
Kenji Watanabe, Takayuki Matsumoto, Tadakazu Hisamatsu, Hiroshi Nakase, Satoshi Motoya, Naoki Yoshimura, Tetsuya Ishida, Shingo Kato, Tomoo Nakagawa, Motohiro Esaki, Masakazu Nagahori, Toshiyuki Matsui, Yuji Naito, Takanori Kanai, Yasuo Suzuki, Masanori Nojima, Mamoru Watanabe, Toshifumi Hibi Akira Andoh, Toshifumi Ashida, Katsuya Endo, Yutaka Endo, Motohiro Esaki, Hiroshi Fujita, Mikihiro Fujiya, Ken Haruma, Toshifumi Hibi, Sakiko Hiraoka, Ichiro Hirata, Tadakazu Hisamatsu, Yutaka Honda, Hideki Iijima, Bunei Iizuka, Kentaro Ikeya, Takuya Inoue, Syuji Inoue, Tetsuya Ishida, Yo Ishiguro, Shyunji Ishihara, Hiroaki Ito, Ryuichi Iwakiri, Takashi Kagaya, Takanori Kanai, Hiroshi Kashida, Shingo Kato, Jun Kato, Takehiko Katsurada, Fukunori Kinjyo, Kiyonori Kobayashi, Mayumi Kodama, Reiko Kunisaki, Koichi Kurahara, Takafumi Kurokami, Lee Kyouwon, Koichiro Matsuda, Kazuhiro Matsueda, Toshiyuki Matsui, Takayuki Matsumoto, Keiichi Mitsuyama, Yuji Mizokami, Satoshi Motoya, Yuji Naito, Tomoo Nakagawa, Shiro Nakamura, Hiroshi Nakase, Masanori Nojima, Masafumi Nomura, Atsuhiro Ogawa, Kazuichi Okazaki, Kazuaki Otsuka, Hirotake Sakuraba, Masayuki Saruta, Makoto Sasaki, Takayuki Shirai, Tomoaki Suga, Kazuhito Sugimura, Toshiro Sugiyama, Yasuo Suzuki, Fuminao Takeshima, Hiroyuki Tamaki, Shinji Tanaka, Satoshi Tanida, Keiichi Tominaga, Taku Tomizawa, Kenji Watababe, Mamoru Watanabe, Kenji Watanabe, Syojiro Yamamoto, Masaki Yamashita, Atsushi Yoshida, Naoki Yoshimura Kenji Watanabe, Takayuki Matsumoto, Tadakazu Hisamatsu, Hiroshi Nakase, Satoshi Motoya, Naoki Yoshimura, Tetsuya Ishida, Shingo Kato, Tomoo Nakagawa, Motohiro Esaki, Masakazu Nagahori, Toshiyuki Matsui, Yuji Naito, Takanori Kanai, Yasuo Suzuki, Masanori Nojima, Mamoru Watanabe, Toshifumi Hibi Akira Andoh, Toshifumi Ashida, Katsuya Endo, Yutaka Endo, Motohiro Esaki, Hiroshi Fujita, Mikihiro Fujiya, Ken Haruma, Toshifumi Hibi, Sakiko Hiraoka, Ichiro Hirata, Tadakazu Hisamatsu, Yutaka Honda, Hideki Iijima, Bunei Iizuka, Kentaro Ikeya, Takuya Inoue, Syuji Inoue, Tetsuya Ishida, Yo Ishiguro, Shyunji Ishihara, Hiroaki Ito, Ryuichi Iwakiri, Takashi Kagaya, Takanori Kanai, Hiroshi Kashida, Shingo Kato, Jun Kato, Takehiko Katsurada, Fukunori Kinjyo, Kiyonori Kobayashi, Mayumi Kodama, Reiko Kunisaki, Koichi Kurahara, Takafumi Kurokami, Lee Kyouwon, Koichiro Matsuda, Kazuhiro Matsueda, Toshiyuki Matsui, Takayuki Matsumoto, Keiichi Mitsuyama, Yuji Mizokami, Satoshi Motoya, Yuji Naito, Tomoo Nakagawa, Shiro Nakamura, Hiroshi Nakase, Masanori Nojima, Masafumi Nomura, Atsuhiro Ogawa, Kazuichi Okazaki, Kazuaki Otsuka, Hirotake Sakuraba, Masayuki Saruta, Makoto Sasaki, Takayuki Shirai, Tomoaki Suga, Kazuhito Sugimura, Toshiro Sugiyama, Yasuo Suzuki, Fuminao Takeshima, Hiroyuki Tamaki, Shinji Tanaka, Satoshi Tanida, Keiichi Tominaga, Taku Tomizawa, Kenji Watababe, Mamoru Watanabe, Kenji Watanabe, Syojiro Yamamoto, Masaki Yamashita, Atsushi Yoshida, Naoki Yoshimura 
Clinical Gastroenterology and Hepatology 
Volume 16, Issue 4, Pages e1 (April 2018)
DOI: /j.cgh
Copyright © 2018 AGA Institute Terms and Conditions

2. Figure 1
Flow chart. Flow chart of the endoscopic subanalysis of the DIAMOND trial. pts, patients.
Clinical Gastroenterology and Hepatology  , e1DOI: ( /j.cgh )
Copyright © 2018 AGA Institute Terms and Conditions

3. Figure 2
Rates of endoscopic response and mucosal healing. Rates of endoscopic response (A) and mucosal healing (B) in the monotherapy group and combination group. Combo, combination therapy group; Mono, monotherapy group.
Clinical Gastroenterology and Hepatology  , e1DOI: ( /j.cgh )
Copyright © 2018 AGA Institute Terms and Conditions

4. Figure 3
Impact of adalimumab trough level. The impact of adalimumab trough level at Week 26 on endoscopic response at Week 26 (A) or Week 52 (B).
Clinical Gastroenterology and Hepatology  , e1DOI: ( /j.cgh )
Copyright © 2018 AGA Institute Terms and Conditions

5. Figure 4
Correlation between quartile of adalimumab trough level and achievement rate. The correlation between quartile of adalimumab trough level at Week 26 and achievement rate of endoscopic response or mucosal healing at Weeks 26 or 52.
Clinical Gastroenterology and Hepatology  , e1DOI: ( /j.cgh )
Copyright © 2018 AGA Institute Terms and Conditions

6. Supplementary Figure 1
Forest plot. Forest plot of the comparison between the monotherapy and combination therapy groups for endoscopic response and mucosal healing.
Clinical Gastroenterology and Hepatology  , e1DOI: ( /j.cgh )
Copyright © 2018 AGA Institute Terms and Conditions